自强化RNA的COVID-19疫苗
Christopher J Wayne1, Anna K Blakney1
1Michael Smith Laboratories, School of Biomedical Engineering, University of British Columbia, BC, Canada.
Cell
|April 12, 2024
概括
日本于2023年11月批准了一种自我放大RNACOVID-19疫苗ARCT-154. 临床试验表明,使用较低剂量的BNT162b2 mRNA疫苗的安全性和疗效相似.
科学领域:
- 疫苗学
- 有关RNA疗法
- 传染病控制
背景情况:
- 由于COVID-19的流行,需要快速开发疫苗.
- mRNA疫苗已经显示出显著的疗效,但需要特殊的储存条件.
- 正在探索新型疫苗平台以提高其可访问性和有效性.
研究的目的:
- 报告ARCT-154的监管批准,这是一种针对COVID-19的新型自我放大RNA疫苗.
- 将ARCT-154的安全性和有效性与现有的mRNA疫苗进行比较.
主要方法:
- 通过日本卫生,劳工和福利部的监管提交和审查过程.
- 对ARCT-154和BNT162b2mRNA疫苗进行比较的临床试验数据分析.
主要成果:
- ARCT-154于2023年11月在日本获得监管批准.
- 临床试验表明ARCT-154的安全性和有效性与BNT162b2mRNA疫苗相比较.
- 较低剂量的ARCT-154可以与BNT162b2疫苗取得相似的结果.
结论:
- ARCT-154代表了COVID-19疫苗技术的重大进展.
- 自放大RNA平台为疫苗开发提供了一个有前途的替代方案.
- 监管部门的批准表明该新候选疫苗的安全性和有效性.
相关概念视频
02:28Leaky Scanning
5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
01:03Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K